Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A. Sallman DA, et al. Among authors: havelange v. Lancet Haematol. 2023 Mar;10(3):e191-e202. doi: 10.1016/S2352-3026(22)00378-7. Epub 2023 Feb 7. Lancet Haematol. 2023. PMID: 36764323 Clinical Trial.
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G, Nédélec A, Vertommen D, Roy A, Marty C, Nivarthi H, Defour JP, El-Khoury M, Hug E, Majoros A, Xu E, Zagrijtschuk O, Fertig TE, Marta DS, Gisslinger H, Gisslinger B, Schalling M, Casetti I, Rumi E, Pietra D, Cavalloni C, Arcaini L, Cazzola M, Komatsu N, Kihara Y, Sunami Y, Edahiro Y, Araki M, Lesyk R, Buxhofer-Ausch V, Heibl S, Pasquier F, Havelange V, Plo I, Vainchenker W, Kralovics R, Constantinescu SN. Pecquet C, et al. Among authors: havelange v. Blood. 2023 Feb 23;141(8):917-929. doi: 10.1182/blood.2022016846. Blood. 2023. PMID: 36356299 Free PMC article.
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Ravandi F, et al. Among authors: havelange v. Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30. Lancet Oncol. 2015. PMID: 26234174 Free PMC article. Clinical Trial.
Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?
Saad Albichr I, De Greef J, Van Den Neste E, Poiré X, Havelange V, Vekemans MC, Bailly S, Yombi JC, Mzougui S, Scohy A, Kabamba-Mukadi B. Saad Albichr I, et al. Among authors: havelange v. Leuk Lymphoma. 2022 Mar;63(3):743-746. doi: 10.1080/10428194.2021.1998485. Epub 2021 Oct 28. Leuk Lymphoma. 2022. PMID: 34706604 Free PMC article. No abstract available.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV. Wang ES, et al. Among authors: havelange v. Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586. Blood. 2022. PMID: 35917453 Free PMC article. Clinical Trial.
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia.
Pötgens SA, Havelange V, Lecop S, Li F, Neyrinck AM, Bindels F, Neveux N, Demoulin JB, Moors I, Kerre T, Maertens J, Walter J, Schoemans H, Delzenne NM, Bindels LB. Pötgens SA, et al. Among authors: havelange v. Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2023.284138. Online ahead of print. Haematologica. 2024. PMID: 38546675 Free article.
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Devos T, Verhoef G, Steel E, Mazure D, Lewalle P, Bron D, Berneman Z, Benghiat FS, Mineur P, Theunissen K, Zachée P, Doyen C, Put N, Lejeune M, Van Eygen K, Havelange V, Reusens M, Pluymers W, Peeters K. Devos T, et al. Among authors: havelange v. Acta Haematol. 2019;142(4):197-207. doi: 10.1159/000499329. Epub 2019 Jun 4. Acta Haematol. 2019. PMID: 31163431 Free article. Clinical Trial.
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T, Havelange V, Theunissen K, Meers S, Benghiat FS, Gadisseur A, Vanstraelen G, Vellemans H, Bailly B, Granacher N, Lewalle P, De Becker A, Van Eygen K, Janssen M, Triffet A, Vrelust I, Deeren D, Mazure D, Bekaert J, Beck M, Selleslag D. Devos T, et al. Among authors: havelange v. Ann Hematol. 2021 Jul;100(7):1723-1732. doi: 10.1007/s00277-021-04507-x. Epub 2021 May 4. Ann Hematol. 2021. PMID: 33942128 Free PMC article.
49 results